Key Takeaways
- The Canadian liquid biopsy market is projected to reach $1.2 billion by 2029, growing at 22% annually from a 2024 base of $380 million.
- GRAIL’s Galleri multi-cancer early detection test has submitted a Health Canada application and expects a decision in late 2026.
- Canadian companies including GeneFirst Diagnostics and Aspect Biosystems are developing competing cfDNA platforms.
- Provincial coverage for liquid biopsy remains fragmented; Ontario and BC have pilot programs for high-risk populations only.
The idea of detecting cancer from a simple blood draw catching tumours before they cause symptoms, before they spread, before the window for curative treatment closes has been one of medicine’s most compelling promises for two decades. It is now arriving as a commercial reality in Canada, with GRAIL’s Galleri multi-cancer early detection test in Health Canada review and a cohort of Canadian companies developing competitive liquid biopsy platforms. The Canadian market opportunity is substantial: an estimated $1.2 billion by 2029 for combined screening and therapeutic monitoring applications.
What Liquid Biopsy Tests Actually Detect
Liquid biopsy is a broad term for tests that detect cancer-derived material circulating in blood or other bodily fluids. The two dominant analytes are circulating tumour DNA (ctDNA) fragments of cancer cell DNA shed into the bloodstream and cell-free DNA (cfDNA), which includes both tumour-derived and normal cell DNA. In cancer screening applications, the test looks for patterns of DNA methylation, fragmentomics, or specific mutation signatures that indicate the presence of cancer tissue. In therapeutic monitoring applications, ctDNA levels are tracked over time to assess treatment response and detect early relapse.
GRAIL’s Galleri test, which detects signals for over 50 cancer types from a single blood draw, is the most advanced multi-cancer early detection product in the regulatory pipeline. A large UK validation study (the SYMPLIFY trial) showed 66.3% overall sensitivity for cancer detection at 98.4% specificity, with sensitivity rising to over 85% for cancers typically detected at late stage. The test’s signal-of-origin algorithm also predicts the tissue of origin of detected cancers with approximately 89% accuracy, enabling rapid diagnostic workup.
| Company | Platform | Technology | Status in Canada | Cancer Types Detected |
|---|---|---|---|---|
| GRAIL (Illumina spin-off) | Galleri | cfDNA methylation | HC review (decision H2 2026) | 50+ cancer types |
| Exact Sciences | Cologuard Plus + liquid | cfDNA + FIT | Colorectal only, available via physician | Colorectal cancer |
| Foundation Medicine (Roche) | FoundationOne Liquid CDx | ctDNA (pan-cancer) | Available as lab-developed test | Therapeutic monitoring |
| GeneFirst Diagnostics (TSX-V) | GF-Detect | cfDNA fragmentomics | Clinical trial phase | Lung, colorectal, ovarian |
| Aspect Biosystems | MethylDetect | cfDNA methylation (AI-enhanced) | Pre-clinical/early clinical | Multi-cancer (research) |
Reimbursement: The Critical Bottleneck
Health Canada clearance is a prerequisite but not a guarantee of patient access. Provincial formularies and the Canadian Drug Agency’s health technology assessment process will determine whether liquid biopsy screening is covered under public insurance plans and the economic case is genuinely complex. At a projected price point of $1,200-$1,800 per Galleri test, covering a recommended annual screening population of even a fraction of at-risk Canadians would represent a multi-hundred-million-dollar commitment from provincial health budgets already under strain.
Ontario’s pilot program, launched in 2025 through Cancer Care Ontario, is screening 3,000 high-risk individuals per year defined as those with strong family history of multiple cancers, known hereditary syndromes, or prior cancer history to generate real-world Canadian data on test performance and health system cost implications. BC Cancer has a smaller pilot running in parallel. These pilots will feed into the national HTA expected in 2027.
The Bottom Line
Liquid biopsy is transitioning from research tool to commercial product in Canada faster than many analysts expected two years ago. The combination of GRAIL’s Health Canada application, active provincial pilots, and an emerging cohort of Canadian companies in the development pipeline suggests that the Canadian liquid biopsy market is approaching an inflection point. The key variables are the Health Canada decision timeline for Galleri, the outcome of provincial HTA processes, and whether any Canadian-developed platform can carve out a competitive position against well-resourced US and European entrants. For investors willing to accept early-stage risk, the Canadian genomics diagnostic space has rarely offered more legitimate near-term catalysts.